IGC Pharma (DB:IGS1) - Stock Price, News & Analysis

IGS1 Stock Overview

A clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. More details

IGS1 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	1/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Revenue is forecast to grow 10.15% per year

Risk Analysis

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have meaningful revenue ($1M)

Does not have a meaningful market cap (€28M)

+ 2 more risks

IGC Pharma, Inc. Competitors

SynBiotic

DUSE:SBX

€27.9m

Biofrontera

XTRA:B8FK

€16.4m

Redx Pharma

DB:0RX

€65.0m

Cantourage Group

XTRA:HIGH

€57.6m

Price History & Performance

Summary of all time highs, changes and price drops for IGC Pharma
Historical stock prices
Current Share Price	US$0.33
52 Week High	US$0.69
52 Week Low	US$0.23
Beta	1.29
11 Month Change	-3.51%
3 Month Change	4.43%
1 Year Change	22.22%
33 Year Change	-72.25%
5 Year Change	-51.87%
Change since IPO	-96.92%

Recent updates

Shareholder Returns

	IGS1	DE Pharmaceuticals	DE Market
7D	6.5%	1.4%	0.8%
1Y	22.2%	-18.4%	9.1%

Return vs Industry: IGS1 exceeded the German Pharmaceuticals industry which returned -19.3% over the past year.

Return vs Market: IGS1 exceeded the German Market which returned 8.5% over the past year.

Price Volatility

Is IGS1's price volatile compared to industry and market?
IGS1 volatility
IGS1 Average Weekly Movement	9.7%
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: IGS1's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: IGS1's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2005	67	Ram Mukunda	igcpharma.com

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer’s disease. The company’s lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023.

IGC Pharma, Inc. Fundamentals Summary

How do IGC Pharma's earnings and revenue compare to its market cap?
IGS1 fundamental statistics
Market cap	€26.27m
Earnings (TTM)	-€11.98m
Revenue (TTM)	€1.13m

24.6x

P/S Ratio

-2.3x

P/E Ratio

Is IGS1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IGS1 income statement (TTM)
Revenue	US$1.18m
Cost of Revenue	US$518.00k
Gross Profit	US$665.00k
Other Expenses	US$13.23m
Earnings	-US$12.57m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.16
Gross Margin	56.21%
Net Profit Margin	-1,062.47%
Debt/Equity Ratio	1.8%

How did IGS1 perform over the long term?

See historical performance and comparison

IGS1 Stock Overview

Rewards

Risk Analysis

IGC Pharma, Inc. Competitors

DUSE:SBX

€27.9m

XTRA:B8FK

€16.4m

DB:0RX

€65.0m

XTRA:HIGH

€57.6m

Price History & Performance

Recent News & Updates

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Second quarter 2025 earnings released: US$0.023 loss per share (vs US$0.045 loss in 2Q 2024)

IGC Pharma, Inc. Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

Independent Director recently bought €179k worth of stock

IGC Pharma, Inc. Advances IGC-AD1 Toward Clinical Trials as a Potential Anti-Amyloid Plaque Treatment for Alzheimer's Disease

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

Recent updates

IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment

Second quarter 2025 earnings released: US$0.023 loss per share (vs US$0.045 loss in 2Q 2024)

IGC Pharma, Inc. Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1

Independent Director recently bought €179k worth of stock

IGC Pharma, Inc. Advances IGC-AD1 Toward Clinical Trials as a Potential Anti-Amyloid Plaque Treatment for Alzheimer's Disease

IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer's Disease

IGC Pharma, Inc. Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist

First quarter 2025 earnings released: US$0.033 loss per share (vs US$0.039 loss in 1Q 2024)

IGC Pharma, Inc., Annual General Meeting, Aug 23, 2024

IGC Pharma's Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

IGC Pharma, Inc., Annual General Meeting, Aug 23, 2024

Full year 2024 earnings released: US$0.22 loss per share (vs US$0.22 loss in FY 2023)

IGC Pharma, Inc.'S TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, A Key Hallmark of Alzheimer's Disease

IGC Pharma, Inc. Announces Patient Enrollment At Neurostudies in Phase 2 Trial Investigating IGC-AD1

IGC Pharma, Inc Announces Interim Data from Its Phase 2 Clinical Trial Demonstrates Clinically Significant Reduction, Approaching Statistical Significance, in Agitation in Alzheimer’S At Week Two Compared to Placebo

IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited

IGC Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $6.24051 million.

Igc Pharma, Inc. Appoints Terry Lierman as Independent Director to Its Board of Directors

Third quarter 2024 earnings released: US$0.088 loss per share (vs US$0.042 loss in 3Q 2023)

IGC Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $5.309602 million.

Igc Pharma, Inc. Activates Clincloud, One of 12 Sites in Ongoing Phase 2B Alzheimer’S Trial

Second quarter 2024 earnings released: US$0.045 loss per share (vs US$0.047 loss in 2Q 2023)

IGC Pharma Expands Phase 2 Trial of IGC-Ad1 to Include the University of Puerto Rico

IGC Pharma, Inc. Presents 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer's Association International Conference

IGC Pharma, Inc. announced that it expects to receive $3 million in funding from Bradbury Asset Management (Hong Kong) Limited and other investors

IGC Pharma, Inc. announced delayed annual 10-K filing

Third quarter 2023 earnings released: US$0.042 loss per share (vs US$0.047 loss in 3Q 2022)

India Globalization Capital, Inc. Receives No Objection Letter from Health Canada

India Globalization Capital, Inc. Announces Board Changes

India Globalization Capital, Inc. Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease

Second quarter 2023 earnings released: US$0.047 loss per share (vs US$0.087 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.054 loss per share (vs US$0.037 loss in 1Q 2022)

India Globalization Capital, Inc., Annual General Meeting, Sep 09, 2022

Full year 2022 earnings released: US$0.30 loss per share (vs US$0.21 loss in FY 2021)

India Globalization Capital, Inc. Receives U.S. Patent for Method and Composition for Treating Seizure Disorders

India Globalization Capital, Inc. Announces Final Approval of Settlement of Shareholder Class Action Lawsuits

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. Common Stock

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. Common Stock

India Globalization Capital, Inc. Announces Positive Primary Endpoint Data for Its Phase 1 Clinical Trial for IGC-AD1

India Globalization Capital, Inc. Announces Preliminary Results for its Exploratory Endpoints from its Phase 1 IGC-AD1 Clinical Trial

India Globalization Capital, Inc. to Present Preliminary Positive Secondary End Point Findings from its Phase 1 Clinical Trial for IGC-AD1

Second quarter 2022 earnings released: US$0.087 loss per share (vs US$0.04 loss in 2Q 2021)

India Globalization Capital, Inc. Completes Its Phase 1 Clinical Trial on Alzheimer’s Patients, Reports Safety and Tolerability

First quarter 2022 earnings released: US$0.037 loss per share (vs US$0.047 loss in 1Q 2021)

India Globalization Capital, Inc Announces Issuance of Patent for the Treatment of Alzheimer’S Disease Using THC

India Globalization Capital, Inc. Completes the Final Cohort of its Phase 1 Clinical Trial on Alzheimer’s Patients

Full year 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in FY 2020)

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

India Globalization Capital, Inc. Completes Cohort 1 of Its Phase 1 Thc-Based Clinical Trial on Alzheimer’S Patients

Independent Chairman of the Board recently sold €75k worth of stock

India Globalization Capital, Inc. Provides Update on Phase 1 Clinical Trial on Alzheimer’S Patients

Third quarter 2021 earnings released: US$0.056 loss per share (vs US$0.041 loss in 3Q 2020)

New 90-day high: €2.09

India Globalization Capital, Inc. Approves the Election of John E. Lynch to the Board of Directors

India Globalization Capital, Inc., Annual General Meeting, Jan 11, 2021

India Globalization Capital, Inc. Commences Phase 1 of Cannabinoid Clinical Trial for Alzheimer’S Patients

India Globalization Capital, Inc. announced delayed 10-Q filing

India Globalization Capital, Inc. announced delayed 10-Q filing